HYDERABAD: Covaxin has been found to be safe, well tolerated and immunogenic in children, with neutralising antibodies found to be on an average 1.7 times higher than in adults. This has come through in data generated by phases II and III paediatric studies on kids aged 2 to 18 years and was uploaded on preprint server medRxiv on Thursday by the vaccine’s developer, Bharat Biotech.
With this, Covaxin has become the only Covid-19 vaccine in the world to have studied and generated data from trials on kids as young as two years. Results of the trial showed seroconversion at 95-98% in children of all age groups, four weeks after they received their second dose. This indicated superior antibody responses in children as compared to adults, Bharat Biotech said.
The researchers said that no serious adverse events were reported in the trials. Of the 526 volunteers that participated in the trials, 374 children reported either mild or moderate symptoms with 78.6% getting resolved within one day, the study said.
